Travere Therapeutics, Inc. (TVTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of TVTX. The 7-day demo opens the 1M and 3M ranges and puts TVTX on your watchlist.
Start 7-day demoLatest TVTX insider trades
About Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- SAN DIEGO, CA
- 497
- 2003
- XNAS
TVTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 46 | 1,060,936 | $67.01M |
| Option exercise | 50 | 1,949,918 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TVTX insider transactions (Form 4)
11478 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher R. Cline - Officer | Option exercise | Common Stock | 4,250 | $0.00 | - | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 2,181 | $46.65 | $102K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 310 | $43.95 | $14K | |
| Christopher R. Cline - Officer | Grant or award | Performance-based restricted stock units | 8,500 | $0.00 | - | |
| Christopher R. Cline - Officer | Option exercise | Performance-based restricted stock units | 4,250 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Common Stock | 9,750 | $6.82 | $66K | |
| Roy D. Baynes | Open-market sale | Common Stock | 9,750 | $44.22 | $431K | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 9,750 | $0.00 | - | |
| William E. Rote - Officer | Open-market sale | Common Stock | 9,100 | $39.09 | $356K | |
| Gary A. Lyons | Option exercise | Common Stock | 8,000 | $16.33 | $131K | |
| Gary A. Lyons | Open-market sale | Common Stock | 8,000 | $41.07 | $329K | |
| Gary A. Lyons | Option exercise | Stock option (right to buy) | 8,000 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Common Stock | 8,000 | $17.94 | $144K | |
| Roy D. Baynes | Option exercise | Common Stock | 9,000 | $15.43 | $139K | |
| Roy D. Baynes | Option exercise | Common Stock | 4,500 | $18.27 | $82K | |
| Roy D. Baynes | Option exercise | Common Stock | 4,500 | $21.38 | $96K | |
| Roy D. Baynes | Option exercise | Common Stock | 6,750 | $17.11 | $115K | |
| Roy D. Baynes | Open-market sale | Common Stock | 26,000 | $41.07 | $1.07M | |
| Roy D. Baynes | Open-market sale | Common Stock | 6,750 | $42.12 | $284K | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 8,000 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 9,000 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 4,500 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 4,500 | $0.00 | - | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 6,750 | $0.00 | - | |
| Sandra Calvin - Officer | Option exercise | Common Stock | 2,500 | $22.40 | $56K | |
| Sandra Calvin - Officer | Option exercise | Common Stock | 6,250 | $8.93 | $56K | |
| Sandra Calvin - Officer | Option exercise | Common Stock | 6,500 | $20.46 | $133K | |
| Sandra Calvin - Officer | Open-market sale | Common Stock | 21,977 | $41.07 | $903K | |
| Sandra Calvin - Officer | Option exercise | Employee stock option (right to buy) | 2,500 | $0.00 | - | |
| Sandra Calvin - Officer | Option exercise | Employee stock option (right to buy) | 6,250 | $0.00 | - | |
| Sandra Calvin - Officer | Option exercise | Employee stock option (right to buy) | 6,500 | $0.00 | - | |
 Peter Heerma - Officer | Grant or award | Common Stock | 14,000 | $0.00 | - | |
| Peter Heerma - Officer | Open-market sale | Common Stock | 7,215 | $41.93 | $303K | |
| William E. Rote - Officer | Grant or award | Common Stock | 14,000 | $0.00 | - | |
| Eric M. Dube - Officer | Grant or award | Common Stock | 64,000 | $0.00 | - | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 56,815 | $41.01 footnote F3 | $2.33M | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 7,165 | $41.75 footnote F4 | $299K | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 20 | $42.66 | $853 | |
| ||||||
 Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $19.08 | $191K | |
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 20,000 | $17.96 | $359K | |
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 7,500 | $15.46 | $116K | |
| Elizabeth E. Reed - Officer | Grant or award | Common Stock | 14,000 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 37,500 | $41.07 | $1.54M | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 7,215 | $41.93 | $303K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 5,226 | $41.62 footnote F5 | $218K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 1,559 | $42.53 footnote F6 | $66K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 7,500 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 20,000 | $0.00 | - | |
| ||||||
| Christopher R. Cline - Officer | Grant or award | Common Stock | 14,000 | $0.00 | - | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 65 | $28.85 | $2K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 9 | $41.07 | $370 | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 7,239 | $41.93 | $304K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 1,014 | $42.61 | $43K | |
 Jula Inrig - Officer | Grant or award | Common Stock | 14,000 | $0.00 | - | |
| Jula Inrig - Officer | Open-market sale | Common Stock | 7,215 | $41.93 | $303K | |
| Jula Inrig - Officer | Open-market sale | Common Stock | 1,018 | $42.61 | $43K | |
| Roy D. Baynes | Option exercise | Common Stock | 10,000 | $26.52 | $265K | |
| Roy D. Baynes | Open-market sale | Common Stock | 10,000 | $33.00 | $330K | |
| Roy D. Baynes | Option exercise | Stock option (right to buy) | 10,000 | $0.00 | - | |
| Eric M. Dube - Officer | Option exercise | Common Stock | 60,000 | $15.46 | $928K | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 34,902 | $30.55 footnote F2 | $1.07M | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 25,098 | $31.46 footnote F3 | $790K | |
| Eric M. Dube - Officer | Option exercise | Employee stock option (right to buy) | 60,000 | $0.00 | - | |
| ||||||
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $15.46 | $155K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 10,000 | $30.00 | $300K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $19.08 | $191K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 10,000 | $28.09 footnote F2 | $281K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Eric M. Dube - Officer | Option exercise | Common Stock | 60,000 | $15.46 | $928K | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 60,000 | $30.10 footnote F2 | $1.81M | |
| Eric M. Dube - Officer | Option exercise | Employee stock option (right to buy) | 60,000 | $0.00 | - | |
| ||||||
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $19.08 | $191K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 5,679 | $27.50 footnote F2 | $156K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 4,321 | $28.26 footnote F3 | $122K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Jula Inrig - Officer | Open-market sale | Common Stock | 1,547 | $32.11 footnote F2 | $50K | |
| Jula Inrig - Officer | Open-market sale | Common Stock | 232 | $32.85 footnote F3 | $8K | |
| ||||||
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 1,635 | $32.14 footnote F2 | $53K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 110 | $32.90 | $4K | |
| ||||||
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 2,485 | $32.07 footnote F2 | $80K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 509 | $32.74 footnote F3 | $17K | |
| ||||||
| Eric M. Dube - Officer | Grant or award | Common Stock | 113,800 | $0.00 | - | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 66,452 | $32.06 footnote F3 | $2.13M | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 33,635 | $32.70 footnote F4 | $1.10M | |
| Eric M. Dube - Officer | Grant or award | Employee stock option (right to buy) | 303,600 | $0.00 | - | |
| ||||||
| Jula Inrig - Officer | Grant or award | Common Stock | 28,130 | $0.00 | - | |
| Jula Inrig - Officer | Open-market sale | Common Stock | 6,956 | $32.12 | $223K | |
| Jula Inrig - Officer | Grant or award | Employee stock option (right to buy) | 75,000 | $0.00 | - | |
| Christopher R. Cline - Officer | Grant or award | Common Stock | 28,130 | $0.00 | - | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 7,242 | $32.12 | $233K | |
| Christopher R. Cline - Officer | Grant or award | Employee stock option (right to buy) | 75,000 | $0.00 | - | |
| Peter Heerma - Officer | Grant or award | Common Stock | 26,120 | $0.00 | - | |
| Peter Heerma - Officer | Open-market sale | Common Stock | 7,310 | $32.12 | $235K | |
| Peter Heerma - Officer | Grant or award | Employee stock option (right to buy) | 69,640 | $0.00 | - | |
| William E. Rote - Officer | Grant or award | Common Stock | 20,090 | $0.00 | - | |
| William E. Rote - Officer | Open-market sale | Common Stock | 12,446 | $32.87 | $409K | |
| William E. Rote - Officer | Grant or award | Employee stock option (right to buy) | 53,570 | $0.00 | - | |
| Sandra Calvin - Officer | Grant or award | Common Stock | 15,180 | $0.00 | - | |
| Sandra Calvin - Officer | Open-market sale | Common Stock | 4,333 | $32.12 | $139K | |
| Sandra Calvin - Officer | Grant or award | Employee stock option (right to buy) | 20,160 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Grant or award | Common Stock | 25,110 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 7,175 | $32.12 | $230K | |
| Elizabeth E. Reed - Officer | Grant or award | Employee stock option (right to buy) | 66,960 | $0.00 | - | |
| Eric M. Dube - Officer | Option exercise | Common Stock | 8,135 | $15.46 | $126K | |
| Eric M. Dube - Officer | Option exercise | Common Stock | 51,865 | $15.46 | $802K | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 8,135 | $30.01 footnote F2 | $244K | |
| Eric M. Dube - Officer | Open-market sale | Common Stock | 51,865 | $30.10 footnote F3 | $1.56M | |
| Eric M. Dube - Officer | Option exercise | Employee stock option (right to buy) | 8,135 | $0.00 | - | |
| Eric M. Dube - Officer | Option exercise | Employee stock option (right to buy) | 51,865 | $0.00 | - | |
| ||||||
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $19.08 | $191K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 10,000 | $27.34 footnote F3 | $273K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
Item 5.02, 9.01
Item 2.02, 9.01
Item 5.02
Item 5.02
Recent TVTX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| PETER HEERMA | Officer | 8,282 | $526K | View on EDGAR | |
| ERIC DUBE | Director, Officer | 108,493 | $6.89M |
TVTX insider trading FAQ
What is the latest insider trade for TVTX?
Travere Therapeutics, Inc. (TVTX) had 10 insider filings in the last 90 days, with the most recent on 2026-09-18. The full record for TVTX runs to 78 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TVTX stock?
No insider purchases of TVTX were filed in the last 90 days.
How many insiders are selling TVTX stock?
46 insider sales of TVTX were filed in the last 90 days, totaling $67.01M.
Where can I see TVTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TVTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - William E. Rote view on EDGAR
- - Peter Heerma view on EDGAR
- - Jula Inrig view on EDGAR
- - Elizabeth E. Reed view on EDGAR
- - Eric M. Dube view on EDGAR
- - Christopher R. Cline view on EDGAR
- - Sandra Calvin view on EDGAR
- - Jeffrey A. Meckler view on EDGAR
- - Christopher R. Cline view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where TVTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TVTX with a 7-day demo
- TVTX on your watchlist
- Every TVTX Form 4 filing on record
- Up to 3 months of TVTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
